Medtronic launches DAPT study for Resolute Onyx DES

Medtronic (NYSE:MDT) said today that it’s launching a study of dual anti-platelet therapy and its Resolute Onyx drug-eluting stent.

The 2,000-patient study is designed to compare a one-month course of aspirin and an anti-coagulant in conjunction with the Resolute Onyx device or another device. The stent is made from a single strand of cobalt alloy, formed into a sinusoidal wave with a radio-opaque core.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic launches DAPT study for Resolute Onyx DES appeared first on MassDevice.

from MassDevice http://ift.tt/2vV1C6m